skip to Main Content

Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Wen Wee Ma, MBBS, professor of oncology, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses first-line treatment considerations in metastatic pancreatic cancer.

Currently, frontline treatment options for patients with metastatic pancreatic cancer consist of FOLFIRINOX or gemcitabine plus nab-paclitaxel (Abraxane), says Ma. Although both regimens were FDA approved based on pivotal clinical trials, they have not yet been compared directly, Ma says. Listen here. . . 

Back To Top